|Day Low/High||74.34 / 74.98|
|52 Wk Low/High||62.66 / 94.98|
Jim Cramer says investors may be misreading the Fed and the moment, but he's got your game plan for earnings season.
Jim Cramer checks in on Starbucks, General Electric, AbbVie, Adaptive Biotechnologies, Vector Group, PBF Energy and more.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?
The most recent short interest data was recently released for the 04/15/2019 settlement date, and AbbVie Inc is the #122 most shorted of the S&P 500 components, based on 5.57 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
AbbVie's deal for Allergan will give it a new revenue stream in Botox, helping offset potential lower revenue from arthritis drug Humira, which is losing patent protection.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
The ActionAlertsPLUS team breaks down what investors need to know on Tueday, including: AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.
After days of complacency, we see a shift in sentiment and folks are getting the jitters.
NEW YORK, June 25, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Allergan Plc ("Allergan" or the "Company") (NYSE: AGN) in connection with the proposed...
AbbVie takes over Allergan. But, it's not the biggest deal of 2019...
Major indexes declined Tuesday after Federal Reserve Chairman Jerome Powell hedged on a possible rate cut.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
AbbVie to purchase botox maker Allergan in $63 billion deal, but is the price just right?
Allergan shares surged the most in more than 25 years Tuesday after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie .
With no other bidder expected to emerge, this is a high risk arbitrage play.
AbbVie is Real Money's Stock of the Day. The biopharmaceutical giant announced a planned $63 billion takeover of Allergan. Action Alerts PLUS Senior Portfolio Analyst Jeff Marks breaks down what investors need to know about the deal.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
Wall Street woke up to another major deal. Here's what to watch from AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's look closer at the charts and indicators of ABBV.
U.S. equity futures drifted lower Tuesday, setting up the S&P 500 for its first three-day decline since early May, as investors peel back from recent record highs and take a defensive stance on risk ahead of this weekend's G20 Summit in Japan.
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
U.S. stock futures decline as investors take a defensive stance on risk ahead of this weekend's G-20 summit in Japan; Micron reports earnings Tuesday; FedEx, which also reports earnings, sues the U.S. government arguing new trade regulations put an 'impossible burden' on the company to monitor its shipments.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.